Find Psychiatry/Psychology Drugs in Phase III Clinical Development in UNITED STATES

Lead Product(s): Cyclobenzaprine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Tonix expects the data to satisfy pharmacokinetic requirements for potential New Drug Applications (NDA) for TNX-102 SL for PTSD and Fibromyalgia.

Lead Product(s): Dextromethorphan,Bupropion

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

STRIDE-1 is a Phase 3, randomized, double-blind, active controlled trial to assess the efficacy and safety of AXS-05 in the treatment of treatment resistant depression.

Lead Product(s): Viloxazine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade